What are the approved and off‑label uses of sildenafil?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Uses of Sildenafil

Sildenafil has two FDA-approved indications: erectile dysfunction (ED) and pulmonary arterial hypertension (PAH), with emerging off-label applications showing promise in various other conditions. 1

FDA-Approved Uses

1. Erectile Dysfunction (ED)

Sildenafil (25 mg, 50 mg, 100 mg tablets) is highly effective for treating ED across diverse patient populations. 2

  • Efficacy: High-quality evidence demonstrates 69% success rate for achieving successful intercourse versus 35.5% with placebo 2
  • Dosing: Start with 50 mg, taken 1 hour before sexual activity; adjust to 25 mg if side effects occur or increase to 100 mg if inadequate response 3
  • Mechanism: Inhibits phosphodiesterase type-5 (PDE5), preventing breakdown of cyclic GMP, thereby enhancing smooth muscle relaxation in the corpora cavernosa 3
  • Patient populations: Effective in men with diabetes, depression, cardiovascular disease, prostate cancer, multiple sclerosis, renal failure, and other conditions 2

Critical contraindication: Never use with nitrates in any form—this combination causes severe, potentially fatal hypotension 3, 1

2. Pulmonary Arterial Hypertension (PAH)

Sildenafil 20 mg three times daily is recommended for improving exercise capacity and functional status in PAH patients. 4, 5, 6

The 2014 CHEST guidelines provide the strongest recommendations:

  • WHO Functional Class II patients: Sildenafil improves 6-minute walk distance (6MWD) (Grade 1C recommendation) 4
  • WHO Functional Class III patients: Sildenafil improves 6MWD (Grade 1B), improves WHO functional class (Grade CB), and improves cardiopulmonary hemodynamics 4
  • Dosing considerations: FDA-approved dose is 20 mg three times daily, though clinical trials showed dose-response up to 80 mg three times daily with greater hemodynamic benefit 4, 6

Key evidence: The SUPER-1 trial (278 patients) demonstrated placebo-corrected improvements of 45-50 meters in 6MWD across all sildenafil doses (20,40,80 mg three times daily), with sustained benefit at 1 year 5, 6

Important caveat: Sildenafil should not be combined with riociguat due to risk of systemic hypotension 4

Off-Label Uses (Emerging Evidence)

3. Pregnancy-Related Conditions

Sildenafil shows benefit in fetal growth restriction and preeclampsia by increasing newborn weight and lowering uterine/umbilical pulsatility indices 7

4. Neonatal/Pediatric Pulmonary Hypertension

Use with extreme caution in children—the FDA warns against pediatric use due to increased mortality risk with long-term therapy. 8, 9, 10

  • European Medicines Agency supports use at "low doses" in children 8
  • Limited evidence in term infants with persistent pulmonary hypertension shows improved oxygenation and reduced mortality (5.9% vs 44%) in low-resource settings without inhaled nitric oxide 9
  • Critical warning: Higher mortality observed in premature infants and with chronic pediatric use 9, 10

5. Other Investigational Uses

Research suggests potential benefits in: 11, 12, 7

  • Heart failure and cardiovascular protection
  • Fatty liver disease
  • Bronchopulmonary dysplasia
  • Premature ejaculation
  • Recurrent spontaneous miscarriage
  • Organ ischemia protection (heart, liver, kidney, brain)

However, these applications lack sufficient clinical trial data for routine clinical use.

Common Side Effects

Mild and generally tolerable: 3, 13

  • Headache, flushing, dyspepsia
  • Nasal congestion, dizziness
  • Visual disturbances (blue-green color discrimination)
  • Myalgias, back pain

Critical Safety Points

  1. Absolute contraindication with nitrates (including recreational "poppers") 1
  2. Seek immediate medical attention for sudden vision or hearing loss 1
  3. Risk of melanoma may be increased 7
  4. Do not combine 20 mg PAH formulation with 25-100 mg ED formulations or other PDE5 inhibitors 1

References

Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2003

Guideline

erectile dysfunction: aua guideline.

The Journal of urology, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.